Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients
- 78 Downloads
We reported a cross-sectional study on causes of liver injury in Japanese type 2 diabetes mellitus (T2D) patients (JG 2013). We assessed overall and cause-specific mortality risk during follow-up of patients enrolled in JG 2013.
This was a longitudinal, multicenter cohort study. Of the 5642 Japanese T2D patients who visited T2D clinics of nine hospitals in the original study, 3,999 patients were followed up for an average of 4.5 years. Expected deaths in T2D patients were estimated using age-specific mortality rates in the general population (GP) of Japan. Standardized mortality ratios (SMRs) were calculated to compare mortality between T2D patients and GP.
All-cancer mortality was significantly higher in T2D patients than in the GP [SMR 1.58, 95% confidence interval (CI) 1.33–1.87]. Among malignancies, hepatocellular carcinoma (HCC) conferred the highest mortality risk in T2D patients (SMR 3.57, 95% CI 2.41–5.10). HCC-associated mortality risk in T2D patients remained significantly high (SMR 2.56, 95% CI 1.64–3.97) after adjusting for high positivity rates of hepatitis B surface antigen (1.7%) and anti-hepatitis C virus (5.3%). In T2D patients with platelet counts < 200 × 103/μl, SMR of HCC increased from 3.57 to 6.58 (95% CI 4.34–9.58). T2D patients with platelet count > 200 × 103/μl showed no increase in mortality risk (SMR 0.68) of HCC.
HCC-associated mortality risk was the highest among all cancers in Japanese T2D patients. Regular follow-up may be important for T2D patients with platelet counts < 200 × 103/μl for early detection of HCC.
KeywordsType 2 diabetes mellitus Hepatocellular carcinoma Mortality risk Platelet count
Type 2 diabetes mellitus
Hepatitis B virus
Hepatitis C virus
Hepatitis B surface antigen
- Anti-HCV Ab
Anti-hepatitis C virus antibody
Standardized mortality ratio
- 95% CI
95% confidence interval
This work was supported by a Grant-in-Aid from the Ministry of Health, Labor, and Welfare, Japan (T. O., H20-Hepatitis-general-008) and the Research Program on Hepatitis from Japan Agency for Medical Research and Development, AMED (T.O.).
Compliance with ethical standards
Conflict of interest
N. Nakamura has received lecture fees from Ono Pharmaceutical Co., Taisho Pharmaceutical Co., and Astra Zeneka. All other authors have no conflicts to report.
- 3.Vital Statistics Japan from Ministry of Health, Labour and Welfare. http://www.e-stat.go.jp/SG1/estat/List.do?lid=000001137965. Accessed 30 Oct 2017.
- 4.Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. http://ganjoho.jp/reg_stat/statistics/dl/index.html. Accessed 30 Oct 2017.
- 6.Shima T, Uto H, Ueki K, et al. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. J Gastroenterol. 2012;48:515–25.CrossRefPubMedGoogle Scholar
- 7.Diabetes C, Complications Trial/Epidemiology of Diabetes I, Complications Study Research G. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care. 2016;39:1378–83.Google Scholar
- 8.Atkinson EJ CC, Pedersen RA, Therneau TM. Poisson models for person-years and expected rates. Technical report #81. http://www.mayo.edu/research/documents/biostat-81pdf/doc-10026981. Accessed 30 Oct 2017.
- 9.Breslow NE, Day NE. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Scientific Publications No. 82. Oxford: Oxford University Press; 1987.Google Scholar
- 27.White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(1342–59):e2.Google Scholar